Close Menu

NEW YORK – Foundation Medicine said on Tuesday that the US Food and Drug Administration has approved its FoundationOne Liquid CDx test as a companion diagnostic for three new targeted cancer therapies. 

The test was approved to help identify patients who may benefit from alpelisib (Novartis' Piqray) in advanced or metastatic breast cancer, rucaparib (Clovis Oncology's Rubraca) in advanced ovarian cancer, and alectinib (Genentech's Alecensa) in a certain kind of metastatic non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.